CCL2 and neoplasm: Particularly, considering only MIBC patients, a positive CCL2 expression in tumor cells was associated with poor mean OS, DSS and recurrence-free survival (RFS), while expression of CCL2 in immune cells, was associated with longer OS, DSS, and RFS (Eckstein et al., 2020).